Adaptive Biotechnologies (NASDAQ:ADPT) Given Buy Rating at Guggenheim

Key Points

• Guggenheim reaffirmed a Buy on Adaptive Biotechnologies with a $21 price target (implying ~50% upside), and the analyst consensus is a "Moderate Buy" with an average target of $19.43.
• Q1 results beat expectations: EPS of -$0.13 vs. -$0.16 est. and revenue of $70.87M (up ~35% YoY), though the company remains unprofitable with negative margins and analysts expect about -0.5 EPS for the year.
• Insider selling and mixed technicals: Insiders sold roughly 2.42M shares (~$34M) in the last 90 days while institutional ownership is high and the stock trades below its 200-day moving average, signaling mixed momentum and confidence.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report)'s stock had its "buy" rating reaffirmed by stock analysts at Guggenheim in a research report issued to clients and investors on Wednesday,Benzinga reports. They currently have a $21.00 price target on the stock. Guggenheim's price objective points to a potential upside of 50.41% from the company's previous close.

Other equities analysts have also recently issued research reports about the company. BTIG Research reiterated a "buy" rating and set a $22.00 target price on shares of Adaptive Biotechnologies in a report on Wednesday. TD Cowen reaffirmed a "buy" rating on shares of Adaptive Biotechnologies in a research report on Wednesday. JPMorgan Chase & Co. lifted their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the company an "overweight" rating in a research report on Friday, February 6th. Wall Street Zen downgraded shares of Adaptive Biotechnologies from a "buy" rating to a "hold" rating in a report on Saturday, March 7th. Finally, Weiss Ratings reissued a "sell (d-)" rating on shares of Adaptive Biotechnologies in a research report on Monday, April 20th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $19.43.

Adaptive Biotechnologies Trading Up 1.3%

Shares of ADPT stock traded up $0.18 on Wednesday, reaching $13.96. The company had a trading volume of 1,372,624 shares, compared to its average volume of 1,938,997. The company has a 50-day moving average of $14.32 and a 200-day moving average of $15.92. The stock has a market cap of $2.23 billion, a PE ratio of -34.44 and a beta of 2.16. Adaptive Biotechnologies has a 12 month low of $8.38 and a 12 month high of $20.76.

Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last issued its quarterly earnings data on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.03. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The business had revenue of $70.87 million for the quarter, compared to the consensus estimate of $61.03 million. During the same quarter last year, the business posted ($0.20) EPS. The firm's revenue was up 35.1% compared to the same quarter last year. Sell-side analysts anticipate that Adaptive Biotechnologies will post -0.5 earnings per share for the current year.

Insider Transactions at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, insider Susan Bobulsky sold 41,338 shares of the firm's stock in a transaction dated Wednesday, March 11th. The shares were sold at an average price of $13.17, for a total value of $544,421.46. Following the transaction, the insider directly owned 427,775 shares of the company's stock, valued at $5,633,796.75. This trade represents a 8.81% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Sharon Benzeno sold 63,103 shares of the business's stock in a transaction that occurred on Wednesday, March 11th. The shares were sold at an average price of $13.17, for a total transaction of $831,066.51. Following the completion of the transaction, the insider owned 272,751 shares of the company's stock, valued at $3,592,130.67. The trade was a 18.79% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 2,417,168 shares of company stock worth $34,153,000. 5.70% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Allianz Asset Management GmbH lifted its position in shares of Adaptive Biotechnologies by 305.8% during the 3rd quarter. Allianz Asset Management GmbH now owns 321,774 shares of the company's stock worth $4,814,000 after buying an additional 242,474 shares during the last quarter. SG Americas Securities LLC boosted its stake in shares of Adaptive Biotechnologies by 82.5% in the 3rd quarter. SG Americas Securities LLC now owns 68,113 shares of the company's stock valued at $1,019,000 after purchasing an additional 30,785 shares in the last quarter. Lisanti Capital Growth LLC acquired a new position in Adaptive Biotechnologies during the 3rd quarter worth approximately $4,476,000. Affinity Wealth Management LLC bought a new position in Adaptive Biotechnologies in the 3rd quarter valued at approximately $4,541,000. Finally, Aristotle Atlantic Partners LLC boosted its position in Adaptive Biotechnologies by 8.6% in the third quarter. Aristotle Atlantic Partners LLC now owns 3,126,719 shares of the company's stock valued at $46,776,000 after buying an additional 247,402 shares in the last quarter. 99.17% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Adaptive Biotechnologies

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Q1 results beat expectations: EPS of -$0.13 vs. -$0.16 est. and revenue of $70.87M (vs. $61.03M est.), with revenue up ~35% year-over-year — management highlighted accelerating MRD adoption as a growth driver. Press Release
• Positive Sentiment: BTIG Research reaffirmed a "buy" rating and set a $22 price target, signaling significant upside in analyst sentiment and supporting the post-earnings rally. BTIG Coverage
• Neutral Sentiment: Full earnings/management commentary and transcripts are available (multiple outlets), which investors can use to parse details on commercialization, MRD traction, and guidance. Earnings Transcript
• Negative Sentiment: Company remains unprofitable: negative net margin and return on equity; EPS is still a loss and analysts expect roughly -0.5 EPS for the year — profitability risk remains. Earnings Summary
• Negative Sentiment: Technical and liquidity notes: the stock remains below its 200-day moving average and intraday volume was under the stock's average, which could limit momentum if follow-through buying fades. Stock Data

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.